Floatz logo

CD47/SIRPA-BLOCKING AGENT ALX148

Metastatic Neoplasm

QuantumLeap Healthcare Collaborativeprotein_peptidePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

144 Active assets in the Metastatic Neoplasm cohort.

Asset / SponsorPhaseRating
Xaliplatin
Ruijin Hospital
Phase 4BBB
Fluorouracilum
Ruijin Hospital
Phase 4BBB
Irinotecan
Eli Lilly and Company
Phase 4BBB
Dexasone
Janssen Research & Development, LLC
Phase 2BBB
Atezolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 2/3BB

View all 49 →

Same molecule, other indications

CD47/SIRPA-BLOCKING AGENT ALX148 is also rated in:

breast cancerActive
B
Indicative · Phase 2
60 / 100
View asset →
plasma cell myelomaActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →
composite lymphomaActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →